BioSpace News Archive

Kaleido Biosciences, Inc. today announced that it will host a virtual R&D Presentation on October 5, 2021, at 8 a.m. ET.

Mindset Pharma Inc. today announced that, in addition to its potential lead new chemical entity (“NCE”) candidate, MSP-4018, the Company has identified two additional pipeline opportunities from its Family 4 compounds, MSP-4019 and MSP-4020.

Prelude Corporation announced today the addition of Karuna Mittal , Ph.D. as Director of Research and Development.

Alnylam Continues Scientific Leadership in Advancement of RNAi Therapeutics at the 17th Annual Meeting of the Oligonucleotides Therapeutics Society

Medable Inc., the leading cloud platform for patient-centered drug development, today announced its Site Network Council (SNC), a select group of clinicians and research leaders who will serve as influential voices in Medable product and services development.

Appili Therapeutics Inc. today announced a strategic alliance to advance the global development of Avigan®/Reeqonus™

Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that members of the Company’s management team will be attending the upcoming virtual Sachs 21st Annual Biotech in Europe Forum (BEF) on October 7th and 8th 2021, and will be available for 1x1 meetings from Monday, October 4th through Friday, October 8th.

Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced new data highlighting the ability of its de novo protein decoy, NL-CVX1, to block SARS-CoV-2 infection in certain viral variants.

Dynamic Digital Radiography (DDR) from Konica Minolta Healthcare Americas, Inc. is rapidly gaining acceptance in spine centers across the US due to its ability to capture the physiological motion of the cervical spine (C-spine) and lumbar spine (L-spine) as a patient moves through the full range of motion.

Galderma announced the presentation of new phase 2 data supporting the efficacy of its investigational monoclonal antibody, nemolizumab, at the virtual 30th EADV congress, taking place between 28 September and 2 October 2021.